A digital view of the world illustrates how Astellas is a global company committed to serving patients worldwide.

News

Astellas is committed to providing timely and accurate information about our business, science and products. This section offers global resources for investors, journalists and media professionals. News and resources from our local affiliates can be viewed in the Local news section. If you are not an investor or journalist, click here.

Month Year

Month Year

Jul 9, 2012

Astellas and XenoPort Announce the Launch of Regnite® Tablets for Restless Legs Syndrome in Japan

Read more
Jul 5, 2012

Contents of Stock Acquisition Rights

(Stock Option Scheme as Stock-Linked Compensation Plan)

Read more
Jul 2, 2012

New public-private partnership to develop a treatment for schistosomiasis-infected preschool children

A newly established international public-private partnership (PPP) between TI Pharma, Merck KGaA (Darmstadt, Germany), Astellas Pharma Inc. and the Swiss Tropical and Public Health Institute...

Read more
Jun 29, 2012

Astellas Obtains Approval in Japan for Treating Prostate Cancer with Gonax® for Subcutaneous Injection

Read more
Jun 28, 2012

FDA Approves Overactive Bladder Treatment Myrbetriq™ (mirabegron) from Astellas

Read more
Jun 26, 2012

ASTELLAS AND MEDIVATION ANNOUNCE EUROPEAN REGULATORY SUBMISSION FOR ENZALUTAMIDE FOR THE TREATMENT OF MEN WITH ADVANCED PROSTATE CANCER POST-CHEMOTHERAPY

Read more
Jun 25, 2012

Astellas Pharma Launches Kiklin® Capsules, a Treatment for Hyperphosphatemia, in Japan

-Provides a New Option for Patients with Hyperphosphatemia-

Read more
Jun 22, 2012

Symbicort® Maintenance And Reliever Therapy for Treatment of Adult Bronchial Asthma Approved in Japan

Read more
Jun 20, 2012

Allotment of Stock Acquisition Rights

(Stock Option Scheme as Stock-Linked Compensation Plan)

Read more
Jun 12, 2012

Astellas and DNDi to Collaborate on New Drug Discovery Research for the Treatment of Neglected Tropical Diseases

Read more
Jun 11, 2012

Astellas Pharma: DIFICLIR™, a Novel Treatment for Clostridium difficile infections (CDI), Launched in Europe

Read more
Jun 6, 2012

Medivation and Astellas Provide Update on PREVAIL Enrollment

Read more
Jun 4, 2012

Astellas and Drais Partner To Develop Second Astellas Compound through Seldar

InterWest Partners, Sutter Hill Ventures and Astellas Venture Management Invest $13 Million into Seldar to Advance Compound

Read more
Jun 4, 2012

AVEO and Astellas Announce TAURUS Patient Preference Clinical Study Comparing Tivozanib with Sunitinib in First-Line Kidney Cancer

Read more
Jun 4, 2012

Agensys and Seattle Genetics Announce Interim Phase I Data from ASG-5ME Clinical Trial for Prostate Cancer

-Dose-Escalation Completed and Preliminary Antitumor Activity Observed

Read more
Jun 4, 2012

Astellas and Ambit Initiate Phase 2b Dose Finding Study of Quizartinib as Monotherapy in Relapsed or Refractory Acute Myeloid Leukemia

Read more
Jun 2, 2012

Medivation and Astellas Announce Enzalutamide Data Relating to Quality of Life Measures and Extension of Time to First Skeletal-Related Event

-- New Data From Phase 3 AFFIRM Trial Presented at ASCO –

Read more
May 21, 2012

Medivation and Astellas Announce Submission of New Drug Application for Enzalutamide for the Treatment of Castration-Resistant Prostate Cancer in Patients Previously Treated with Chemotherapy

Read more
May 18, 2012

Medivation and Astellas Announce Enzalutamide (Formerly MDV3100) Data to Be Presented at ASCO Annual Meeting 2012

Read more
May 16, 2012

AVEO and Astellas Announce Positive Findings from TIVO-1 Superiority Study of Tivozanib in First Line Advanced RCC

- Tivozanib is the First Agent to Demonstrate Greater than One Year PFS in Patients without Prior Systemic Treatment -

Read more
May 10, 2012

Issuance of Stock Acquisition Rights for Stock Option Scheme under Stock-Linked Compensation Plan

Read more
May 7, 2012

Astellas Announces Favorable Ruling in Patent Infringement Case

Read more
Apr 26, 2012

Astellas Nominates Directors

Read more
Apr 25, 2012

Astellas and Drais Partner To Develop Astellas Compound through Telsar

InterWest Partners, Sutter Hill Ventures and Astellas Venture Management Invest $14 Million into Telsar to Advance Compound

Read more
Apr 5, 2012

FDA Advisory Committee Recommends Approval of Mirabegron – Investigational Overactive Bladder Treatment from Astellas

Read more

Show per page

Discover more

Return to media homepage

Follow us

Subscribe to news alerts